Intralesional Vitamin D3 Injection in the Treatment of Recalcitrant Warts: A Novel Proposition.
J Cutan Med Surg. 2017 Apr 1:1203475417704180. doi: 10.1177/1203475417704180.
Raghukumar S1, Ravikumar BC1, Vinay KN1, Suresh MR1, Aggarwal A1, Yashovardhana DP1.
1 Department of Dermatology, Hassan Institute of Medical Sciences, Hassan, Karnataka state, India.
- The study only tried to treat “recalcitrant warts” = not treated by conventional means
- Appears that the study used an average of 3.7 injections of 8,000 to 40,000 IU per recalcitrant wart
- After 6 months 90% of the previous recalcitrant warts were totally gone and 7% per partially gone
- 100% of “distant” warts were removed
- Herpes virus infection while pregnant increases Autism risk by 2 X (Vitamin D not mentioned) – Feb 2017
VitaminDwiki suspects that topical Vitamin D will also treat warts.
Wife has just started topical vitamin D oil applied daily to a 20-year wart on her finger.
Gave up after a few days - too hard to keep the liquid on the tip of her finger
I suggested that she apply the liquid to band-aid gauze, but she did not try
She also applied Vitamin D to a mole on her arm, which quickly went away
Verruca vulgaris (viral warts) is a fairly common condition with a plethora of treatment options having variable success rates. Recalcitrant warts are refractory to treatment with often disappointing response and high recurrence rates. Lately, treatment with intralesional injections has gained momentum due to its effectiveness in clearing warts by stimulating the cell-mediated immunity. Vitamin D, when applied topically, regulates epidermal cell proliferation and is involved in the formation of antimicrobial peptides. We have attempted to use vitamin D3 to exploit its reported action as an immunotherapeutic molecule in addition to its topical effects. To our knowledge, there are no reports of intralesional vitamin D3 injections used in the treatment of extragenital recalcitrant warts.
Sixty-four patients with recalcitrant warts of varying sizes and duration were included in the study. About 0.2- to 0.5-mL vitamin D3 solution (600,000 IU, 15 mg/mL) was injected to the base of the wart. A maximum of 5 warts were injected per session at 3-week intervals until resolution or for a maximum of 4 treatments. Patients were followed up for 6 months after the last injection to detect any recurrence.
Sixty patients completed the study. Complete response was seen in 54 of 60 (90%), partial response in 4 of 60 (6.66%), and no response in 2 of 60 (3.33%). The average number of injections required to achieve a complete resolution was 3.66. Complete resolution of distant warts was noticed in all patients.
Intralesional vitamin D3 is a safe, effective, and an inexpensive treatment option for recalcitrant warts.
PMID: 28384048 DOI: 10.1177/1203475417704180
Safety and efficacy of intralesional vitamin D3 in cutaneous warts: An open uncontrolled trial
J Cutan Aesthet Surg 2017;10:90-4 Year : 2017 | Volume : 10 | Issue : 2 | Page : 90-94
Manjunath Kavya, Basavapura Madegowda Shashikumar, Muddanahalli Rajegowda Harish, Bhadbhade P Shweta
Department of Skin and STD, Mandya Institute of Medical Sciences, Mandya, Karnataka, India
Two images in study via Google Images
Background: Cutaneous warts are treated primarily with destructive methods such as cryotherapy or electrocautery. These modalities of treatment are time-consuming and may be associated with scarring in multiple warts. Immunotherapy is emerging as a new modality of treatment which acts on enhancing cell-mediated immunity against human papillomavirus for clearance of both treated and distant warts.
Aims: This study aims to evaluate the safety and efficacy of intralesional Vitamin D3 for the treatment of cutaneous warts. Materials and Methods: Patients with multiple warts were selected for immunotherapy. Vitamin D3 (0.2 ml, 15 mg/ml) was injected to the base of warts after injecting with lignocaine (0.2 ml, 20 mg/ml). The injections were repeated 2 weeks apart for a maximum of 4 sessions or until complete clearance, whichever was earlier. A maximum of 2 warts were treated per session and patients were followed up for 6 months after the last injection.
Results: Forty-two patients with multiple warts were recruited for the study who completed the 6-month follow-up period and were available for analysis. Of these, 23 had palmoplantar warts, 18 had verruca vulgaris and 1 patient had filiform wart. In total, 33 of 42 patients (78.57%) showed complete response, 6 patients (14.28%) showed moderate response and three patients (7.14%) showed mild response. Recurrence was observed in one patient with the palmoplantar wart. No serious adverse effects were reported. Limitations: Lack of control group was the main drawback in our study.
Conclusion: Intralesional Vitamin D3 is safe and effective for treatment of multiple cutaneous warts.
Comparative clinical study of the efficacy of intralesional MMR vaccine vs intralesional vitamin D injection in treatment of warts
Journal of Cosmetic Dermatology https://doi.org/10.1111/jocd.13272
Dalia R. Shaldoum MBBCh Ghada F. R. Hassan MD Eman H. El Maadawy MD Gamal M. El‐Maghraby MD
Background: Many therapeutic modalities were reported for the treatment of warts; however, no single treatment is completely effective.
Objective: To evaluate the efficacy of intralesional injection of MMR vaccine vs vitamin D in treatment of warts.
Patients and Methods
A total of 60 patients were included in the study divided into two groups. Group A received intralesional MMR vaccine into largest wart, and group B received intralesional vitamin D3 into each lesion with maximum of five warts treated in one session. A maximum of six sessions was done every 3 weeks in both groups. Follow‐up was done for 6 months for any recurrence.
In group A: complete response in 80%, partial response in 6.67%, minimal response in 6.67%, and no response in 6.67% of patients. About 60% of patients with multiple warts showed complete clearance of distant untreated warts.
In group B: complete response in 66.7%, partial response in 6.67%, minimal response in 20%, and no response in 6.67% of patients.
There was no significant difference between both groups. No recurrence was observed in both groups in the follow‐up period.
Immunotherapy by both intralesional MMR vaccine and vitamin D3 is simple, well‐tolerated, effective, and cost‐benefit modalities for the treatment of warts.
- Wart Wikipedia
" Warts are typically small, rough, and hard growths that are similar in color to the rest of the skin”
“Warts are caused by infection with a type of human papillomavirus (HPV)”
“The estimated current rate of non-genital warts among the general population is 1–13%”
- 40% of warts eliminated by Vitamin D injection, but less in smokers Jan 2019 10.1111/dth.12816
- How To Treat Recalcitrant Plantar Warts 2013
“The treatment of warts can be very challenging.”
“ Many warts fail to respond to conventional treatment and after several months are considered recalcitrant.”
“Warts (verrucae) involve the epithelium of the skin and are caused by infection with the human papillomavirus (HPV). Warts are the most common viral infection of the skin, affecting 7 to 10 percent of the general population.”
- Close to Half of American Adults Infected With HPV, Survey Finds New York Times, April 2017
Download the PDF with nice charts from Vitamin D Life
- Could 25-OH vitamin D deficiency be a reason for HPV infection persistence in cervical premalignant lesions? ResarchGate, PDF online
- Association Between Serum 25-Hydroxyvitamin D Level and Human Papillomavirus Cervicovaginal Infection in Women in the United States June 2016
- Successful Treatment of Anogenital Wart with a Topical Vitamin D3 Derivative in an Infant April 2010]
Successful for an infant, as well as elderly - taking weeks to months, free PDF online
- TAKING A LOOK AT USING VITAMINS TO CURE THE COMMON WART Oct 2017
Vitamin A with or without salicylic acid
- How to Get Rid of Warts Naturally Dr. Axe; perhaps 20 ways, does not mention Vitamin D
There have actually been
|2588 visitors, last modified 11 Jan, 2020, |